Condition: Cancer · Sponsor: Beyond Air Inc.
This is a Phase 1, open-label, dose-escalation and dose-expansion study comprised of a screening period, a single treatment session, an evaluation period of 21±3 days, and safety and survival follow-up period of up to 12 weeks post-treatment.
This description comes directly from the study's public registry record.
Edith Dekel · 972-50-8464449 · edekel@beyondcancer.com
Yaara Ber, PhD · yber@beyondcancer.com
Always discuss trial participation with your own doctor first.
| Soroka Medical Center | Beersheba, Israel | Recruiting |
| Hadassah Ein-Karem | Jerusalem, Israel | Recruiting |
| Sheba Medical Center | Ramat Ef‘al, Israel | Recruiting |
| Sourasky Tel Aviv Medical Center | Tel Aviv, Israel | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05351502